Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) - April 14, 2025 Deadline to Join - Contact The Gross Law Firm

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, which has been discontinued following a company reorganization [1][2]. Group 1: Company Developments - The class period for the lawsuit is from July 30, 2024, to January 8, 2025, during which Intellia allegedly provided investors with optimistic timelines for the NTLA-3001 study [2]. - On January 9, 2025, Intellia announced a halt to all NTLA-3001 research and a 27% workforce reduction, indicating a shift in focus to other pharmaceutical developments [2]. - Following the announcement, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to$10.20 per share on January 10, 2025 [2]. Group 2: Legal Proceedings - Shareholders who purchased shares during the class period are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [3]. - Participants in the class action will be enrolled in a portfolio monitoring system to receive updates on the case [3]. - The Gross Law Firm, which is leading the class action, aims to protect investors' rights and recover losses incurred due to misleading statements by the company [4].